Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
kit inhibitormedical
A kit inhibitor is a medicine that blocks the KIT protein, a switch on some cells that tells them to grow and divide. Investors care because drugs that shut off this switch can treat cancers and other diseases driven by KIT; successful kit inhibitors can create new revenue streams but also carry risks from side effects, competition, and resistance—like replacing a faulty thermostat in a building to stop overheating but needing the right fit and maintenance.
type 2 immune diseasesmedical
Type 2 immune diseases are conditions driven by an overactive branch of the immune system that responds to harmless substances—think of a sprinkler system that keeps dousing the house because it mistakes steam for fire. Common examples include allergic asthma and eczema; the misdirected response causes inflammation and tissue damage. Investors watch these diseases because they create demand for targeted medicines, diagnostics and long-term care solutions, making them a major area for drug development and recurring revenue.
mast cell-mediatedmedical
Mast cell-mediated describes a biological process driven by mast cells, a type of immune cell that releases signaling chemicals (like histamine) to cause allergic or inflammatory reactions. For investors, this label signals that a drug, test or condition targets a specific immune mechanism — similar to fixing a sprinkler that keeps going off — which affects how well a therapy might work, its safety profile, and the size of the market opportunity.
target-engagementmedical
Target-engagement is evidence that a drug or treatment physically interacts with the biological molecule or site it was designed to affect, like a key fitting a specific lock in the body. For investors, strong target-engagement data is an early sign the therapy is working as intended, which lowers development risk and increases the likelihood that later clinical results and regulatory approval will follow.
pharmacokinetic profilemedical
The pharmacokinetic profile describes how a drug moves through the body over time, including how quickly it is absorbed, how it spreads, and how it is eventually eliminated. For investors, understanding this profile helps gauge the drug’s effectiveness, safety, and the appropriate dosing schedule, which can influence a company’s potential success and market value. It provides insight into how a medication behaves, impacting its overall commercial viability.
WATERTOWN, Mass.--(BUSINESS WIRE)--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for EDP-978, the Company’s KIT inhibitor in development for the treatment of mast cell-mediated, Type 2 immune diseases, will be presented in two poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held February 27 – March 2, 2026 in Philadelphia, PA.
Details of the presentations are as follows:
Abstract Title: Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases
Date: Friday, February 27, 2026
Time: 2:45 – 3:45 PM EST
Poster Number: 104
Session: Allergic Skin Diseases
Location: Convention Center, Level 2, Hall E
Presenter: Tessa Cressey, Ph.D.
Abstract Title: EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-Dependent Target-Engagement and a Favorable Pharmacokinetic Profile with Once-Daily Dosing Potential in Humans
Date: Friday, February 27, 2026
Time: 2:45 – 3:45 PM EST
Poster Number: 038
Session: Allergic Skin Diseases
Location: Convention Center, Level 2, Hall E
Presenter: Yang Li, Ph.D.
Abstracts are available in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) platform here. Further information about AAAAI 2026 can be found here. Posters will be available on Enanta’s website here after presentations are held on February 27, 2026.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
